Grom et al. Emapalumab (anti-IFNg) in MAS in Stills. 39 patient pooled analysis. 54% complete response at week 8, 85% at any time. Clinically meaningful glucocorticoid reduction in 72%. @RheumNow #ACR24 Abstr#L19 https://t.co/U72KCfsUh7 https://t.co/jNxsvhseVf
Links:
Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activa…
https://acrabstracts.org/abstract/efficacy-and-safety-of-emapalumab-in-children…
19-11-2024